Navigation Links
Stage at Breast Cancer Diagnosis Will Shift Dramatically Over the Next 20 Years in Key Latin American Markets
Date:11/5/2013

BURLINGTON, Mass., Nov. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with increased awareness and investment in national breast cancer screening programs, the stage at diagnosis of breast cancer in the key Latin American markets is set to shift dramatically over the next 20 years. According to findings from the Strategic Insights report The Impact of Economic Growth on Patient Populations: Breast Cancer Populations in Latin America, the drug-treatable breast cancer patient population will also increase, driven by a rapidly expanding and aging population and earlier stages at diagnosis. Specifically, the adjuvant and neoadjuvant drug-treatable population will increase by 51 percent and the first-line drug-treatable population will increase by 21 percent over the next 10 years.

The findings also reveal that in the adjuvant and neoadjuvant setting in Brazil and Mexico, with HR+ and HER2-overexpressing tumors present in 70 percent and 22 percent of Latin American breast cancer cases, respectively, the growth in hormone therapy and HER2-targeted agents is expected to increase by 51 percent over the next 10 years.

"The risk of breast cancer will increase in Brazil and Mexico as they become more affluent and adopt more-Westernized lifestyles—a key indicator of breast cancer risk," said Decision Resources Senior Epidemiologist Alison Isherwood, Ph.D. "The increasing population, increasing risk of breast cancer and shifting to earlier stages at diagnosis are all driving the increase in the drug-treatable breast cancer populations, so marketers of breast cancer drugs will find significant opportunity in this region."

Countries included in the analysis are Argentina, Brazil, Chile, Colombia, Mexico and Venezuela.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
4. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
5. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
6. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
7. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
8. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
9. Telescope Implant for End Stage Macular Degeneration Now Available Across the Nation
10. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
11. Pharmaceutical Packaging is at the Centre Stage of Pharma Manufacturing!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):